Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs

Basit Öğe Kaydı
dc.authorid0000-0001-7275-8724
dc.contributor.authorSaltoğlu, Neşe
dc.contributor.authorDinç, Harika Öykü
dc.contributor.authorBalkan, İlker İnanç
dc.contributor.authorCan, Günay
dc.contributor.authorÖzbey, Doğukan
dc.contributor.authorBeytur, Ayşe Nur
dc.contributor.authorKeskin, Elif
dc.contributor.authorBudak, Beyhan
dc.contributor.authorAydoğan, Okan
dc.contributor.authorMete, Bilgül
dc.contributor.authorKaraali, Rıdvan
dc.contributor.authorErgin, Sevgi
dc.date.accessioned2022-08-08T07:10:53Z
dc.date.available2022-08-08T07:10:53Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Mikrobiyoloji Ana Bilim Dalı
dc.description.abstractThe objective of our study was to evaluate the antibody responses of health care workers (HCWs) who were vaccinated with booster dose BNT162b2 6 months after 2 doses of the CoronoVac vaccine. The study included 318 HCWs vaccinated with inactive CoronaVac SARS-CoV-2 vaccine in 2 doses. Anti-spike/RBD IgG levels were measured immediately before and 1 month after the booster dose. In the sixth month after CoronaVac vaccination, the median of antibody levels of 1212.02 AU/ML, while it was 9283 AU/mL after BNT162b2 vaccination. IgG antibody titers of over 1050 AU/mL (which is equivalent to 1:80 dilution in the plaque reduction neutralization test) were detected in HCWs 15.09% and 97.8%, respectively. Our results showed that antibody titers increased 8-fold after the booster dose. We believe that the administration of the mRNA vaccine as a booster dose can provide more effective protection against COVID-19 infection, especially in individuals with risk factors.
dc.description.sponsorshipIU-Cerrahpaşa Scientific Research Projects Uniten_US
dc.identifier.citationSaltoğlu, N., Dinç, H. Ö., Balkan, İ. İ., Can, G., Özbey, D., Beytur, A. N. ... Ergin, S. (2022). Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs. Diagnostic Microbiology and Infectious Disease, 104(2). https://doi.org/10.1016/j.diagmicrobio.2022.115758
dc.identifier.doi10.1016/j.diagmicrobio.2022.115758
dc.identifier.issn0732-8893
dc.identifier.issue2
dc.identifier.pmid35878507
dc.identifier.scopus2-s2.0-85134734769
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1016/j.diagmicrobio.2022.115758
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9636
dc.identifier.volume104
dc.identifier.wos000834101500001en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAydoğan, Okan
dc.language.isoen
dc.publisherElsevier Inc.
dc.relation.ispartofDiagnostic Microbiology and Infectious Diseaseen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAntibody
dc.subjectBNT162b2
dc.subjectCoronaVac
dc.subjectCOVID-19
dc.subjectVaccine
dc.titleHeterologous booster COVID-19 vaccination elicited potent immune responses in HCWs
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Aydogan-Okan-2022.pdf
Boyut:
321.02 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu